Evidence map›Paper›PMID 12562379›Full record

ArticleClinical and experimental immunology2003

Interleukin 10 induced augmentation of delayed-type hypersensitivity (DTH) enhances Mycobacterium bovis bacillus Calmette-Guérin (BCG) mediated antitumour activity.

R Nadler, Y Luo, W Zhao, J K Ritchey, J C Austin, M B Cohen, M A O'Donnell, T L Ratliff

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical and experimental immunology, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
4.6field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 60 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Immunotherapeutic strategies for bladder cancer.Human vaccines & immunotherapeutics · 2014
    Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

R NadlerDepartment of Urology, Northwestern University, Chicago, IL, USA.
Y Luo
W Zhao
J K Ritchey
J C Austin
M B Cohen
M A O'Donnell
T L Ratliff
University of Iowa · USNorthwestern University · USWashington University in St. Louis · US

Funding

INTRAVESICAL BCG FOR BLADDER CANCER: ROLE OF FIBRONECTINR01CA044426 · NCI · WASHINGTON UNIVERSITY · PI RATLIFF, TIMOTHY L · 1988 to 1998
–
CYTOKINE RECOMBINANT BCG FOR BLADDER CANCER THERAPYR29CA064230 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI O'DONNELL, MICHAEL A · 1994 to 1998
–
INTRAVESICAL BCG FOR BLADDER CANCER--ROLE OF FIBRONECTINR55CA044426 · NCI · JEWISH HOSPITAL OF SAINT LOUIS · PI RATLIFF, TIMOTHY L · 1991 to 1991
–
NCI NIH HHS CA44426NCI NIH HHS R29CA64230
6 · The paper itself

Abstract

Intravesical BCG therapy is effective in the treatment of superficial bladder cancer. Both clinical and experimental results suggest a role for cytokines and delayed-type hypersensitivity (DTH) in BCG-induced antitumour immunity. We characterized the modulatory effects of BCG on bladder cytokine expression and determined the relationship between DTH and BCG antitumour activity. The bladders of mice were instilled with BCG through a catheter. Bladder tissue RNA and urine were collected for evaluation of cytokine expression using reverse transcriptase-polymerase chain reaction (RT-PCR) and/or ELISA. IFN-gamma and TNF-alpha, the two major cytokines associated with DTH, were efficiently induced by BCG. IL10, an important down-regulator of DTH, was also induced by BCG. Constitutive levels of IL4 and IL5 were observed, but neither IL4 nor IL5 were modulated by BCG. Similar results were observed in the kinetic analysis of urinary cytokines in patients after intravesical BCG therapy. Production of Th1 (T helper type 1) cytokines (IFN-gamma, IL2 and IL12) preceded that of the Th2 (T helper type 2) cytokine IL10. A tendency toward higher ratios of IFN-gamma versus IL10 for BCG responders also was observed. In animal studies the absence of IL10 abrogated either by antibody inhibition or the use of genetically modified, IL10 deficient (IL10-/-) mice resulted in enhanced DTH responses. Under conditions of enhanced DTH, a significant enhancement in antitumour activity was observed. These data demonstrate that DTH and its associated mononuclear infiltration and cytokine production are important to the antitumour activity of intravesical BCG therapy, and suggest that effects to diminish IL10 production may have therapeutic value.

Indexed as

AnimalsBCG VaccineFemaleHypersensitivity, DelayedInterferon-gammaInterleukin-10MiceMice, Inbred C57BLReverse Transcriptase Polymerase Chain ReactionTumor Necrosis Factor-alphaUrinary BladderUrinary Bladder NeoplasmsBCG VaccineInterferon-gammaInterleukin-10Tumor Necrosis Factor-alpha

Identifiers

PMID12562379
PMCPMC1808633
OpenAlexW2059773548

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.